Literature DB >> 6818015

Drug interactions with valproic acid.

R H Levy, K M Koch.   

Abstract

Valproic acid undergoes drug-drug interactions with most of the commonly used anticonvulsants. Since it possesses a wide range of indications, concomitant use with other anticonvulsants, and hence interactions, are not infrequent. Many of these interactions are reciprocal and may have important therapeutic consequences. Valproate acts as a protein binding displacer and/or metabolic inhibitor with respect to a number of other anticonvulsants (phenobarbitone, primidone, phenytoin). Inhibition of metabolism would, in most instances, result in a decrease of the dose requirements of the affected drugs. Valproate is a low clearance drug primarily eliminated by metabolism. Its metabolism is highly inducible by some of the major anticonvulsants (e.g. carbamazepine, phenytoin). Valproate is also highly protein bound in plasma and thus is displaced by salicylates and free fatty acids. However, displacement alone, unlike induced metabolism, should not affect the drug's dose-response relationship.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6818015     DOI: 10.2165/00003495-198224060-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  60 in total

1.  Serum protein binding of valproic acid and its displacement by palmitic acid in vitro.

Authors:  A Monks; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

2.  Simple gas-chromatographic measurement of valproic acid in psychiatric patients: effect on levels of other simultaneously administered anticonvulsants.

Authors:  R Varma; A Y Hoshino
Journal:  Neurosci Lett       Date:  1979-03       Impact factor: 3.046

3.  Controlled trial of sodium valproate in severe epilepsy.

Authors:  A Richens; S Ahmad
Journal:  Br Med J       Date:  1975-11-01

4.  The effect of acetylsalicylic acid on serum free valproate concentrations and valproate clearance in children.

Authors:  K Farrell; J M Orr; F S Abbott; S Ferguson; I Sheppard; W Godolphin; J Bruni
Journal:  J Pediatr       Date:  1982-07       Impact factor: 4.406

5.  [Serum phenobarbital levels in epileptics].

Authors:  P Loiseau; A Brachet; P Henry
Journal:  Encephale       Date:  1975       Impact factor: 1.291

6.  Sodium valproate in the treatment of resistant epilepsy.

Authors:  M N Hassan; H C Laljee; M J Parsonage
Journal:  Acta Neurol Scand       Date:  1976-09       Impact factor: 3.209

7.  Plasma protein binding interaction between phenytoin and valproic acid in vitro.

Authors:  A Monks; S Boobis; J Wadsworth; A Richens
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

8.  Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.

Authors:  C Knott; A Hamshaw-Thomas; F Reynolds
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-02

9.  Modification of phenytoin clearance by valproic acid in normal subjects.

Authors:  G M Frigo; S Lecchini; G Gatti; E Perucca; A Crema
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

10.  Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects.

Authors:  E Perucca; S Hebdige; G M Frigo; G Gatti; S Lecchini; A Crema
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

View more
  26 in total

1.  In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).

Authors:  X Wen; J S Wang; K T Kivistö; P J Neuvonen; J T Backman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

Review 2.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

3.  Effect of febrile illness and its treatment on anticonvulsant levels in children.

Authors:  K J Goulden
Journal:  CMAJ       Date:  1986-06-15       Impact factor: 8.262

4.  Serum protein binding of tolbutamide in patients treated with antiepileptic drugs.

Authors:  M C Fernández; S Erill; M I Lucena; E Pita; N Pérez-Alférez
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 5.  Adverse drug interactions.

Authors:  M J Brodie; J Feely
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-19

Review 6.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.

Authors:  M Oellerich; H Müller-Vahl
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 8.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

9.  A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.

Authors:  E Perucca; A Hedges; K A Makki; M Ruprah; J F Wilson; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

10.  Steady-state carbamazepine plasma concentration-dose ratios in epileptic patients.

Authors:  A Sánchez; J A Durán; J S Serrano
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.